VDJ001 is a proprietary IL-6R antibody drug independently developed by the company. This product has received significant governmental support, including the National Major New Drug Innovation Project (exclusive), the Beijing Municipal Science and Technology Commission’s Major New Drug Innovation Project (exclusive), and the Zhongguancun Frontier Project, among other key initiatives. It has also been included in the Beijing Municipal Medical and Health Reserve Project. 

VDJ001 is a proprietary IL-6R antibody drug independently developed by the company. This product has received significant governmental support, including the National Major New Drug Innovation Project (exclusive), the Beijing Municipal Science and Technology Commission’s Major New Drug Innovation Project (exclusive), and the Zhongguancun Frontier Project, among other key initiatives. It has also been included in the Beijing Municipal Medical and Health Reserve Project. 

 VDJ001 has successfully completed Phase II clinical studies for both rheumatoid arthritis (RA) and the rare disease idiopathic multicentric Castleman disease (iMCD). The clinical outcomes have been excellent, with data demonstrating superiority over existing international therapies in key indicators. 

 Currently, VDJ001 has entered the enrollment stage for its pivotal Phase III clinical study. Its international patent (PCT) has been granted in multiple countries and regions, including China, the United States, Japan, South Korea, and Australia. Upon future approval and market launch, VDJ001 is expected to deliver significant clinical value and social benefits for both the nation and patients.